Carbonic Anhydrase Inhibitors as Antithrombotic Agents (CAIATA)

• Research type

  Research Study

• Full title

  Carbonic Anhydrase Inhibitors as Antithrombotic Agents (CAIATA): A prospective single centre controlled study investigating the antiplatelet potential of acetazolamide and methazolamide in adult acute glaucoma patients

• IRAS ID

  213199

• Contact name

  Alastair Poole

• Contact email

  a.poole@bristol.ac.uk

• Sponsor organisation

  Head of Research Governance, University of Bristol

• Duration of Study in the UK

  0 years, 8 months, 28 days

• Research summary

  What is the purpose of the study?
  This study will help work out whether glaucoma medication namely acetazolamide or metazolamide may be repurposed to control platelet mediated blood clotting disorders.

  What are blood platelets and how do they cause thrombosis or clots?
  Platelets are small cells within the blood that are involved in the clotting mechanism. After an injury, healthy platelets become activated (switched on). This makes the platelets undergo dramatic changes in shape and ‘skin’ composition. These changes help them promote the formation of a clot that eventually stops the bleeding at wound sites.

  In some situations platelets can become activated when they should not be and this can lead to the formation of clots in important blood vessels, which may cause a heart attack or stroke. We now have a better understanding of why this occurs. In this study we aim to examine the possibility that glaucoma medications may actually help treat or prevent these events.

  What research question are we trying to answer?
  The study objective is to examine the antiplatelet effects of acetazolamide and methazolamide in adult glaucoma patients administered these drugs for short term treatment.

  We are conducting this study to address the initial question of whether acetazolamide or methazolamide exert an antithrombotic effect, at clinical doses, in humans. We may also be able to determine whether glaucoma drug is likely to provide advantage over aspirin and clopidogrel, currently used to manage clotting disorders. Positive information will provide a reason to progress the study to a broader study assessing these effects in more people.

• REC name

  East Midlands - Nottingham 1 Research Ethics Committee

• REC reference

  16/EM/0515

• Date of REC Opinion

  15 Dec 2016

• REC opinion

  Favourable Opinion